Drug Profile
Research programme: cancer therapeutics - Tarveda Therapeutics
Alternative Names: Pentarins™Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Blend Therapeutics
- Developer Tarveda Therapeutics
- Class Antineoplastons
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors; Somatostatin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuroendocrine tumours; Small cell lung cancer; Solid tumours
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Neuroendocrine-tumours in USA
- 28 Aug 2020 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in USA
- 28 Aug 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA